Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Teva Pharmaceutical Industries Ltd ADR (TEVA)

Teva Pharmaceutical Industries Ltd ADR (TEVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,929,969
  • Shares Outstanding, K 1,103,330
  • Annual Sales, $ 15,878 M
  • Annual Income, $ 417,000 K
  • 60-Month Beta 1.18
  • Price/Sales 0.59
  • Price/Cash Flow 2.29
  • Price/Book 0.91
Trade TEVA with:

Options Overview Details

View History
  • Implied Volatility 43.82% ( +5.66%)
  • Historical Volatility 44.88%
  • IV Percentile 42%
  • IV Rank 16.37%
  • IV High 110.53% on 10/12/21
  • IV Low 30.76% on 08/05/21
  • Put/Call Vol Ratio 0.45
  • Today's Volume 6,444
  • Volume Avg (30-Day) 11,998
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 1,605,861
  • Open Int (30-Day) 1,533,079

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate 0.55
  • Number of Estimates 5
  • High Estimate 0.58
  • Low Estimate 0.51
  • Prior Year 0.57
  • Growth Rate Est. (year over year) -3.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.23 +25.59%
on 05/12/22
9.21 -1.41%
on 05/26/22
+0.29 (+3.30%)
since 04/26/22
3-Month
7.23 +25.59%
on 05/12/22
10.50 -13.52%
on 04/08/22
+0.72 (+8.61%)
since 02/25/22
52-Week
7.23 +25.59%
on 05/12/22
11.55 -21.35%
on 06/10/21
-1.54 (-14.50%)
since 05/26/21

Most Recent Stories

More News
Teva Reaches Agreement With West Virginia to Settle the State’s Opioid-Related Claims

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and its affiliates, has reached an agreement with the Attorney General of West Virginia that settles...

TEVA : 9.08 (+0.89%)
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®

Alvotech Holdings S.A. (“Alvotech”), a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, today announced positive results from...

OACB : 9.97 (+0.20%)
TEVA : 9.08 (+0.89%)
Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual Meeting

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new efficacy and safety data from a 3-year open-label extension (OLE) study on AUSTEDO...

TEVA : 9.08 (+0.89%)
United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼

Teva Pharmaceutical Industries Ltd welcomes the UK Medicines & Healthcare Regulatory Agency (MHRA) decision to grant a licence for Ongavia ® , a biosimilar to Lucentis ® (ranibizumab ), an eye injection....

TEVA : 9.08 (+0.89%)
Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Annual Meeting

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced four data presentations for AUSTEDO ® (deutetrabenazine) tablets and TV-46000/mdc-IRM....

TEVA : 9.08 (+0.89%)
Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced new study findings based on newly established clinical thresholds on short-acting beta agonist...

TEVA : 9.08 (+0.89%)
Teva Pharmaceutical Industries: Why Investors Should Buy the Dip

Shares of Teva Pharmaceutical (TEVA) have plunged in price due to the company’s weak financials and its reduction of its top-line guidance. However, can the stock rebound by the company leveraging its...

MRK : 92.31 (-1.54%)
NVO : 106.60 (+1.28%)
NVS : 91.26 (+0.01%)
TEVA : 9.08 (+0.89%)
Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®

Alvotech Holdings S.A. (“Alvotech”), a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, today announced positive top-line results...

OACB : 9.97 (+0.20%)
TEVA : 9.08 (+0.89%)
Options Plays for Earnings This Week

This week we have some big retail names reporting in Home Depot (HD), Walmart (WMT) and Target (TGT). Over the last few weeks, we’ve seen some big moves over earnings, particularly in growth and bitcoin...

HD : 302.81 (+3.15%)
WMT : 126.00 (+2.13%)
TGT : 163.20 (+4.33%)
SE : 79.55 (+5.07%)
JD : 52.72 (+5.04%)
LOW : 195.53 (+3.70%)
CSCO : 44.99 (+2.25%)
AMAT : 115.07 (+6.03%)
DE : 347.51 (+1.32%)
FL : 32.70 (+1.90%)
TEVA : 9.08 (+0.89%)
MNTV : 11.92 (+2.23%)
Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Help Inform Treatment Decisions at American Thoracic Society 2022 Annual Meeting

Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new findings will be presented at the 2022 American Thoracic Society (ATS)...

TEVA : 9.08 (+0.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets,...

See More

Key Turning Points

3rd Resistance Point 9.42
2nd Resistance Point 9.31
1st Resistance Point 9.20
Last Price 9.08
1st Support Level 8.98
2nd Support Level 8.87
3rd Support Level 8.76

See More

52-Week High 11.55
Fibonacci 61.8% 9.90
Fibonacci 50% 9.39
Last Price 9.08
Fibonacci 38.2% 8.88
52-Week Low 7.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar